(NEW YORK) — Eli Lilly’s next generation of weight loss drugs appear to show promise, possibly leading to even faster weight loss and added health benefits, early trial results suggest.

The pharmaceutical company presented the results for its newer drug at the annual ObesityWeek conference on Thursday.

Known as amylin analogs, these drugs slow digestion and curb appetite, similar to the more well-known GLP-1 drugs, but act through a different hormone.

Amylin is a hormone that is co-secreted with insulin through the pancreas and helps regulate blood glucose levels, appetite and gastric emptying, which is the process of food moving from the stomach to the intestines.

These drugs can treat type 2 diabetes and obesity by imitating the body’s natural amylin.

While the effects are similar t

See Full Page